Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer's Disease.

Journal: Journal of Alzheimer's disease : JAD
PMID:

Abstract

BACKGROUND: The ideal participants for Alzheimer's disease (AD) clinical trials would show cognitive decline in the absence of treatment (i.e., placebo arm) and also would be responsive to the therapeutic intervention being studied (i.e., drug arm). One strategy to boost the power of trials is to enroll individuals who are more likely to progress targeted using data-driven predictive models.

Authors

  • Ali Ezzati
    Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Richard B Lipton
    Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.